Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Yunguang Sun MD, PhD
Assistant Professor
Department of Pathology
Division of Administration

OFFICE ADDRESS:
Translational and Biomedical Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226
Phone: 414-955-7587
Email: ysun@mcw.edu

EDUCATION:
09/1993 - 06/1998 M.D., Nanjing Medical University, Nanjing, Jiangsu
09/1998 - 06/2003 Ph.D., Fudan University, Shanghai, China

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
08/2003 - 07/2008 Visiting Fellow, Clinical Endocrinology Branch, NIDDK, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892
08/2008 - 05/2011 Research Fellow, Department of Radiation Oncology, Vanderbilt University, 2201 West End Ave, Nashville, TN 37235
05/2011 - 10/2014 Research Associate, Department of Radiation Oncology, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107
11/2014 - 06/2015 Research Associate, Department of Cancer Biology, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107

MILITARY SERVICE:
N/A

FACULTY APPOINTMENTS:
06/2015 - Present Assistant Professor, Department of Pathology, The Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226

ADMINISTRATIVE APPOINTMENTS:
N/A

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
N/A

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
N/A

RESEARCH ADMINISTRATIVE APPOINTMENTS:
N/A

HOSPITAL STAFF PRIVILEGES:
N/A

AWARDS AND HONORS:
2008 - Present NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) Fellow Scientific Retreat Travel Awards, NIH (National Institutes of Health)
06/2010 - Present VICTR (Vanderbilt Institute for Clinical and Translational Research) resource award, ID: VR1780, VR1376, VR967, supported by Vanderbilt CTSA grant UL1 RR024975 from NCRR/NIH (2010)

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
06/2009 - 06/2010 Sigma Xi
01/2010 - 12/2011 Associate member (American Association of Cancer Research)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
11/21/2018 - Present Journal of Veterinary Science and Research
02/11/2019 - Present Scientific Reports
Journal Review
06/2010 - Present Cell Biology International
06/2010 - Present Journal of Oncology
2011 - Present International Journal of Biological Sciences
2011 - Present Clinical Medicine Insights: Oncology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
N/A

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
N/A

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Molecular determinants of double tamoxifen and trastuzumab resistance in ER positive breast cancer
Source:
American Cancer Society Institutional Research Grant
Role:
PI
PI:
Yunguang Sun
Dates:
01/01/2017 - 12/31/2018
Direct Funds:
$50,000
 

PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
L. Moretti, Y. Sun, L. Mitchell, B. Lu,, Terameprocol a Novel Survivin Inhibitor Leads to Radiosensitization of Non-Small Lung Cancer, Annual Meeting & Program Committee of the American Society for Radiation Oncology (ASTRO),, Chicago IL, 11/01/2009 - 11/05/2009
L. Moretti, Y. Sun, B. Lu,, TG-AZ1, a Novel JAK2 Inhibitor Inhibits Survivin and Enhances Radiation Therapy in Non-Small Lung Cancer, American Thoracic International Conference, New Orleans, LA, 05/14/2010 - 05/19/2010
Y. Sun, Y. Zheng, C. Speris,B. Lu, Genetic profiling of lung cancer stem-like cells reveals IGF signaling pathway as a promising target for therapeutic resistance, Annual Meeting & Program Committee of the American Society for Radiation Oncology (ASTRO), San Diego, CA, 10/31/2010 - 11/04/2010
K. Nowak, Y. Sun, M. Werner‐Wasik, A. P. Dicker,B. Lu, PF02340166 Inhibits ALK Downstream Effectors And Increases Sensitivity To Radiation In Cells Harboring The EML4‐ALK Fusion., Annual Meeting & Program Committee of the American Society for Radiation Oncology (ASTRO), Boston, MA, 10/28/2012 - 11/01/2012
 
International
L. Moretti, Y. Sun, B. Lu,, Targeting of STAT3 and survivin with TG101209 a novel JAK2 inhibitor enhances radiotherapy in lung cancer models., Annual Congress of European Respiratory Society (ERS), Barcelona, Spain, 09/18/2010 - 09/22/2010
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Stephen Matthew Schleicher (Grade IV), Vanderbilt University, 01/2010 - 06/2010 Capacity (Research mentor).
Nicholas Giacalone (Grade II), Vanderbilt University, 01/2010 - 06/2010 Capacity (Research mentor).
Chia-Lin Winchester, Thomas Jefferson University, 01/2012 - 06/2012 Capacity (Research mentor).
Kunal Dalal, Thomas Jefferson University, 01/2012 - 06/2012 Capacity (Research mentor).
Kamilla Nowak, Thomas Jefferson University, 01/2012 - 06/2012 Capacity (Research mentor).
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Sun Y, Tao YG, Kagan BL, He Y, Simons S. Modulation of parameters for glucocorticoid receptor-mediated repression by factors that also modulate receptor-mediated induction. Molecular and Cellular Endocrinology. 2008, 295(1-2):59-69.
2. Sun Y, Moretti L, Giacalone NJ, Schleicher S, Speirs CK, Carbone DP, Lu B. J Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models. J Thorac Oncol. 2011; 6(4):699-706.
3. Sun Y, Giacalone N, Lu B. Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J Thorac Oncol. 2011; 6(1):8-14.
4. Morrison R, Schleicher S, Sun Y, Niermann K, et al. Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis. Journal of Oncology, 2011; doi:10.1155/2011/941876.
5. Sun Y, Zheng S, Speris C, et al. The Role of Igf-1 Signaling Pathway in Cisplatin-Resistant Lung Cancer Cells. International Journal of Radiation Oncology, Biology, Physics. 2012;82(3):e563-72.
6. Sun Y, Nowak K, Werner-Wasik M, et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Molecular Cancer Therapeutics. Published Online First on February 26, 2013; DOI: 10.1158/1535-7163.MCT-12-0868
7. Zhang Z‎‎; Sun Y, Cho Y‎‎; Chow C; Simons S. PA1: a New Competitive Decelerator Acting at More Than One Step To Impede Glucocorticoid Receptor-Mediated Transactivation. Journal of Biological Chemistry. 2013: 288(1), 42-58. (Co-first author)
8. Sun Y, Myers CJ, Dicker AP, Lu B. A Novel Radiation-Induced p53 Mutation Is Not Implicated in Radiation Resistance via a Dominant-Negative Effect. PLoS ONE 2014; 9(2): e87492. doi: 10.1371/journal.pone.0087492
9. Wang Y, Sun Y, Justin B, Solomides, C, Zhan T, Lu B. Nitrilase 1 modulates lung tumor progression in vitro and in vivo. Oncotarget. 2016 Mar 10. doi: 10.18632/oncotarget.7820 [Epub ahead of print] (Co-first author)
10. Gonyo P, Bergom C, Brandt AC, Tsaih SW, Sun Y, Bigley TM, Lorimer EL, Terhune SS, Rui H, Flister MJ, Long RM, Williams CL. SmgGDS is a transient nucleolar protein that protects cells from nucleolar stress and promotes the cell cycle by regulating DREAM complex gene expression. Oncogene. 2017 12 14;36(50):6873-6883. PMCID: PMC5730474
11. Lakshmikuttyamma A, Sun Y, Lu B, Undieh AS, Shoyele SA. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles. Mol Pharm. 2014 Dec 01;11(12):4415-24.
12. Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shyr Y, Dicker AP, Lu B. IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Mol Cancer Res. 2017 07;15(7):896-904.
13. Wang YA, Sun Y, Le Blanc JM, Solomides C, Zhan T, Lu B. Nitrilase 1 modulates lung tumor progression in vitro and in vivo. Oncotarget. 2016 Apr 19;7(16):21381-92. PMCID: PMC5008292
14. Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clin Cancer Res. 2018 12 15;24(24):6355-6366.
15. Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci U S A. 2018 10 02;115(40):E9298-E9307. PMCID: PMC6176615
16. Schlaak RA, Frei A, Schottstaedt AM, Tsaih SW, Fish BL, Harmann L, Liu Q, Gasperetti T, Medhora M, North PE, Strande JL, Sun Y, Rui H, Flister MJ, Bergom C. Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. Am J Physiol Heart Circ Physiol. 2019 06 01;316(6):H1267-H1280. PMCID: PMC6620678
17. Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Res Treat. 2019 Aug;177(1):77-91.
18. Wright KD, Miller BS, El-Meanawy S, Tsaih SW, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H, Flister MJ, Sorokin A. The p52 isoform of SHC1 is a key driver of breast cancer initiation. Breast Cancer Res. 2019 06 15;21(1):74. PMCID: PMC6570928
19. Liu N, Wang YA, Sun Y, Ecsedy J, Sun J, Li X, Wang P. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines. Respir Res. 2019 Oct 23;20(1):230. PMCID: PMC6813099
20. Schlaak RA, Frei A, Fish BL, Harmann L, Gasperetti T, Pipke JL, Sun Y, Rui H, Flister MJ, Gantner BN, Bergom C. Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on Injury. Cancers (Basel). 2020 Apr 16;12(4). PMCID: PMC7226421
21. Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol Ther. 2020 Jul 02;21(7):629-636. PMCID: PMC7515508
22. Cho C, Mukherjee R, Peck AR, Sun Y, McBrearty N, Katlinski KV, Gui J, Govindaraju PK, Puré E, Rui H, Fuchs SY. Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. Oncogene. 2020 Sep;39(38):6129-6137. PMCID: PMC7502515
23. Chen K, Jiao X, Ashton A, Di Rocco A, Pestell TG, Sun Y, Zhao J, Casimiro MC, Li Z, Lisanti MP, McCue PA, Shen D, Achilefu S, Rui H, Pestell RG. The membrane-associated form of cyclin D1 enhances cellular invasion. Oncogenesis. 2020 Sep 18;9(9):83. PMCID: PMC7501870
 
Non-Refereed Journal Publications/Original Papers
1. Li W, Li B, Giacalone NJ, Torossian A, Sun Y, et al. BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non-small Cell Lung Carcinoma In Vitro. J Thorac Oncol. 2011; 6(11): 1801-9.
2. Niermann K, Moretti L, Giacalone N, Sun Y, et al. Enhanced Radiosensitivity of Androgen-Resistant Prostate Cancer: AZD1152-Mediated Aurora Kinase B Inhibition, Radiat Res. 2011 175(4):444-51
3. Li B, Torossian A, Sun Y, et al. Higher Levels Of C-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity To Amg-458, A Novel Selective C-Met Inhibitor With Radiosensitizing. International Journal of Radiation Oncology, Biology, Physics. 2012; 84(4): e525-e531.
4. Zaorsky NG, Sun Y, Wang Z, Palmer J, Fortina PM, Solomides C, Werner-Wasik M, Dicker AP, Axelrod R, Campling B, et al. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biology & Therapy 2013; 14:883 - 887; PMID: 23917487; http://dx.doi.org/10.4161/cbt.25942
5. Li B, Le Blanc J, Sun Y, Yang L, Zaorsky N, Giacalone N, Torossian A, Lu B.Assessment of M867, a selective caspase-3 inhibitor, in an orthotopic mouse model for non-small cell lung carcinoma. Am J Cancer Res 2014;4(2):161-171
 

jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a